Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ali_Health
|
| gptkbp:acquisition |
various biotech firms
|
| gptkbp:awards |
numerous industry awards
|
| gptkbp:business_model |
innovative business model
|
| gptkbp:capital |
significant market capitalization
|
| gptkbp:ceo |
Sun Piaoyang
|
| gptkbp:clinical_trial |
conducts numerous clinical trials
invests heavily in clinical research generates extensive clinical data |
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:community_engagement |
active in community engagement programs
|
| gptkbp:economic_activity |
experiences consistent business growth
|
| gptkbp:employees |
over 10,000
|
| gptkbp:exported_to |
exports to over 30 countries
|
| gptkbp:feedback |
prioritizes customer satisfaction
|
| gptkbp:financial_performance |
strong financial performance
|
| gptkbp:focus |
gptkb:healthcare_organization
pain management imaging diagnostics |
| gptkbp:founded |
gptkb:1997
|
| gptkbp:global_presence |
has a global presence
|
| gptkbp:headquarters |
gptkb:Lianyungang,_Jiangsu,_China
|
| gptkbp:healthcare |
provides innovative healthcare solutions
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jiangsu Hengrui Medicine
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:innovation |
known for innovation in drug development
|
| gptkbp:invention |
holds many patents
|
| gptkbp:investment |
makes significant investments in R& D
|
| gptkbp:leadership |
holds a leadership position in the market
|
| gptkbp:market |
global
|
| gptkbp:marketing_strategy |
aggressive market strategy
|
| gptkbp:partnerships |
international pharmaceutical companies
strategic partnerships with healthcare providers has clinical partnerships with hospitals |
| gptkbp:philanthropy |
engages in philanthropic activities
|
| gptkbp:population_trend |
monitors market trends closely
|
| gptkbp:product_line |
diverse product lines
|
| gptkbp:products |
oncology drugs
diagnostic imaging agents focuses on product development anesthesia drugs |
| gptkbp:provides_information_on |
follows clinical guidelines
|
| gptkbp:regulatory_compliance |
ensures regulatory compliance
receives regulatory approvals globally |
| gptkbp:research_and_development |
focus on innovative drugs
|
| gptkbp:research_areas |
operates multiple research facilities
covers multiple therapeutic areas |
| gptkbp:revenue |
over 1 billion USD
|
| gptkbp:safety_features |
adheres to high safety standards
|
| gptkbp:social_responsibility |
engages in community health initiatives
|
| gptkbp:specialties |
committed to clinical excellence
|
| gptkbp:stock_exchange |
gptkb:Shanghai_Stock_Exchange
|
| gptkbp:subsidiary |
multiple subsidiaries worldwide
|
| gptkbp:supply_chain |
efficient supply chain management
effective supply chain management |
| gptkbp:sustainability |
committed to sustainable practices
|
| gptkbp:technology |
utilizes advanced technology in production
|
| gptkbp:training |
invests in employee training programs
|
| gptkbp:treatment |
aims to improve clinical outcomes.
|
| gptkbp:type_of_care |
focus on improving patient care
|